Home › Funds › TCG Crossover Management, LLC › TRDA
TCG Crossover Management, LLC position in TRDA
ENTRADA THERAPEUTICS INC · Health Care
TCG Crossover Management, LLC reported holding 1,060,230 shares of TRDA (ENTRADA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.7M, representing 0.19% of its reported portfolio and ranking #44 among its reported holdings. TCG Crossover Management, LLC has disclosed TRDA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How TCG Crossover Management, LLC's TRDA position evolved
TCG Crossover Management, LLC first disclosed a stake in TRDA in Q3 2023 at 584,955 shares (US$9.2M). The position peaked in Q1 2026 at 2,287,500 shares, worth US$28.9M. Across 13 filings, TCG Crossover Management, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 1,060,230 shares valued at US$6.7M. Notable position changes include a 257% increase in Q4 2025 (shares rose 23% over the following quarter), a 54% trim in Q2 2026 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 584.96K | $9.24M | New |
| Q4 2023 | 584.96K | $8.83M | Hold |
| Q1 2024 | 584.96K | $8.29M | Hold |
| Q2 2024 | 584.96K | $8.34M | Hold |
| Q3 2024 | 584.96K | $9.35M | Hold |
| Q4 2024 | 584.96K | $10.11M | Hold |
| Q1 2025 | 584.96K | $5.29M | Hold |
| Q2 2025 | 584.96K | $3.93M | Hold |
| Q3 2025 | 584.96K | $3.39M | Hold |
| Q4 2025 | 2.09M | $21.47M | Add |
| Q1 2026 | 2.29M | $28.87M | Add |
| Q2 2026 | 1.06M | $7.80M | Reduce |
| Q3 2026 | 1.06M | $6.73M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRDA and 13F data
TRDA (ENTRADA THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in TRDA — the largest reported positions include BAKER BROS. ADVISORS LP (US$37.3M), 5AM Venture Management, LLC (US$29.9M), Merck & Co., Inc. (US$11.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRDA
- BAKER BROS. ADVISORS LP 5.07M sh · $37.34M · Q2 2026
- 5AM Venture Management, LLC 4.06M sh · $29.85M · Q2 2026
- Merck & Co., Inc. 1.74M sh · $11.05M · Q3 2026
- MPM BioImpact LLC 1.25M sh · $9.22M · Q2 2026
- Trails Edge Capital Partners, LP 1.43M sh · $9.07M · Q3 2026
- StepStone Group LP 761.28K sh · $5.60M · Q2 2026
- Lynx1 Capital Management LP 178.61K sh · $1.31M · Q2 2026
More on TCG Crossover Management, LLC
FAQ
How long has TCG Crossover Management, LLC held TRDA?
TCG Crossover Management, LLC has disclosed TRDA holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is TCG Crossover Management, LLC's current position in TRDA?
As of Q3 2026, TCG Crossover Management, LLC holds 1.06M shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $6.73M, representing 0.19% of its reported portfolio and ranking #44.
Has TCG Crossover Management, LLC been buying or selling TRDA?
In the latest 13F filing (Q3 2026), TCG Crossover Management, LLC held unchanged its position in TRDA. The position peaked in Q1 2026 at 2.29M shares.
Which other funds hold TRDA?
Other major institutional holders of TRDA include BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, Merck & Co., Inc., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.